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Introduction
Humanity is preoccupied with extending life. There are supplements, exercises, diets and
retreats that cater to this goal. Film, television, and novels explore how we might one day
become immortal, or go extinct. When novel infectious diseases develop, humanity declares a
world health emergency and countries across the globe unite to prevent its progression. In the
United States, millions of dollars are committed to analyzing mortality and morbidity data so that
public health officials can propose solutions to the one impending problem we all share - death.
There is rarely protest to these measures, undertaken to protect humanity from early deaths.1
The leading causes of death in the United States have been heart disease and cancer for
many years.2 In 2016 and 2017, the number of individuals who died from either condition tripled
that of the next most common cause of death.2 Physicians regularly attribute heart disease and
cancer to lifestyle choices, including diet, smoking, alcohol consumption, and exercise.3-4
Individuals can also be predisposed to both conditions through certain genetic mutations, which
increase their risk of disease development.3-4 However, the role that distinct genetic disease plays
in the leading causes of death is rarely discussed.
Hereditary hemochromatosis (HH) is a genetic disease that causes both heart disease and
cancer, despite often being ignored in the diagnosis of both conditions. In fact, of the ten most
common causes of death in 2016 and 2017, HH is associated with an increased risk of almost
half of the listed conditions.2-5 Despite the association of this disease with common fatal
complications, HH is also severely underdiagnosed.5-6 This is the result of a lack of physician
and patient familiarity with the disease. For many years, HH was only identified as an unusual
characteristic of autopsies; the role that it played during life was unknown.5 Although it is the
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most common genetic disease in people of Caucasian descent (it may be present in 10-15% of
some populations), it is rarely considered when doctors are presented with its early symptoms.7
This lack of appropriate diagnosis results in unnecessary and unrecognized mortality, which
could easily be prevented with appropriate screening protocol and improved education.
HH remains severely underdiagnosed despite the clear benefit of early diagnosis and
treatment. There are currently no established screening programs for HH anywhere in the world.
Although several European countries have previously attempted to justify screening programs,
none of them have been successful. This analysis outlines the major risks and benefits of such a
screening program in the United States using the foundational principles of medical bioethics autonomy, justice, beneficence, and nonmaleficence. Each fundamental principle is introduced
generally, then applied more specifically to a potential HH screening program.
Before the analysis can begin, the term “genetic testing” needs to be defined. A genetic
test is an analysis of a human sample - typically DNA - used to detect certain heritable diseases
for clinical purposes.8-10 There are three varieties of genetic testing: diagnostic, predictive, and
carrier.11 Diagnostic testing identifies a current disease state - for example, current prenatal and
newborn genetic screening.11 Predictive testing confirms the presence of a genetic mutation that
will result in a disorder with delayed onset, typically in individuals with a positive family
history.10-11 Carrier testing determines if an individual, typically with no family history, has a
certain genetic trait, which may affect progeny.10-11 Currently, HH testing is almost exclusively
diagnostic. An effective HH screening program will also serve as predictive and carrier testing.
What follows is a brief introduction to HH, which will be critical to the understanding of
the remainder of this analysis.
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Hereditary hemochromatosis (HH)
HH is a genetic disease characterized by unusually efficient dietary iron absorption.12-13
Essentially, the body absorbs more iron than it can use. This excess iron progressively
accumulates throughout the body, especially in organs and joints.7, 13 The resulting condition massive iron overload - leads to serious health concerns, including organ failure and death.7, 12
HH is caused by certain genetic mutations. The most commonly expressed mutation is
HFE C282Y, a mutation on chromosome six.5, 7, 14 There are additional mutations, including
H63D, which are common in the gene pool but expressed at much lower levels.14 Although the
mechanism of the mutated HFE protein remains somewhat unclear, recent research suggests it
regulates hepatic production of hepcidin, a key iron-regulatory hormone.5, 13, 15 Hepcidin binds
ferroportin, the sole protein responsible for transporting iron across cellular membranes.5, 15 In a
normal individual, when the duodenum absorbs sufficient iron, hepcidin binds to ferroportin and
halts additional iron uptake.15 In individuals with HH, hepatic production of hepcidin is
decreased, so the critical hepcidin-ferroportin binding does not sufficiently occur.16 The result is
an excess of intra- and extracellular iron. Biochemically, this can be observed through elevated
serum ferritin and transferrin saturation.5
Iron is a necessary element for healthy human life. However, in excess - such as in the
blood of HH patients - it is toxic. Excess free iron produces reactive oxygen species and
abnormal iron forms, which are known to cause organ damage and alter hepatic mitochondrial
function.5 In particular, abnormal iron forms are associated with disturbance of the metabolism
of other metals, including zinc.5 Parenchymal cells appear particularly sensitive to these effects,
but under high enough iron concentrations, all cells begin to suffer detrimental effects.5
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Disease progression in HH patients varies widely, and is heavily dependent on the point
in the individual’s life at which they are diagnosed. For some, the disease is secondarily
identified in screenings for other conditions, and symptoms never present.17 However, other
patients die from complications of the disease without ever being diagnosed. This apparent
discrepancy is the result of incomplete penetrance: although many individuals have the genetic
mutation for HH, not all of those individuals will express symptoms of the disease.18
HH typically begins with chronic fatigue and joint pain.5 As the disease progresses,
osteoporosis, frequent bacterial and viral infections, and melanoderma are common.5 Late stages
of the disease are characterized by the most severe symptoms, which include cardiac
disturbances (including rhythm abnormalities, cardiomyopathies, and cardiac failure), liver
cirrhosis and cancer, rheumatoid arthritis, and diabetes mellitus.5, 6, 19 Without monitoring and
treatment, HH patients often die as a result of these disease complications.
The early symptoms of HH are easily attributed to other conditions, including stress. As a
result, HH is rarely diagnosed early in its progression based off symptoms alone.5-6 By the time
the disease reaches its most severe stages, the complications are typically attributed to other
well-known factors, such as lifestyle and predisposition mutations.
This chronic issue of misdiagnosis is particularly devastating because the disease is easily
treatable. HH treatment requires phlebotomy, or periodic removal of venous blood.5 Phlebotomy
is extremely effective, safe, and cheap. Additionally, blood from HH phlebotomy can be used to
save lives via transfusion with very few exceptions.5 Most individuals who begin phlebotomy
therapy early in life report never experiencing the severe complications associated with the
disease; members of this group who do experience complications almost exclusively develop
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mild arthropathies.5 Treatment can begin in most HH patients at age sixteen, and maintenance
only requires a few phlebotomy sessions each year and annual laboratory testing.5 In the United
States, the cost of phlebotomy varies widely by geographic location, but in most urban areas
there are free blood donation centers that can be utilized by HH patients. For patients who do not
respond well to phlebotomy, there are also a variety of effective iron chelating pharmaceuticals,
although these are frequently associated with severe side effects.5 Affected individuals are also
continuously monitored on an annual basis once treatment is established as effective and safe.
HH diagnosis is simple. Genetic analysis at any point in an individual’s life will reveal
the presence of the mutations that cause HH. Biochemical tests - specifically serum ferritin and
transferrin saturation - can be highly suggestive of the disease, but are only accurate predictors
once disease progression has begun, and must be confirmed with genetic testing.5 Therefore, the
simplest method for detecting HH is genetic testing early in life. This will allow individuals to
begin treatment as early as possible, massively reducing their risk of developing fatal
complications. With all of this in mind, HH appears to be an obvious choice for newborn genetic
screening. However, as mentioned above, there are a variety of bioethical issues that have
prevented the development of a genetic screening program for HH and similar conditions.
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Autonomy
Medical autonomy refers to a patient’s right to make all of their own decisions - without
fear of coercion or coaxing - with regards to their personal healthcare.20 Theoretically, all
medical decisions should be voluntary and made under the conditions of informed consent, and
all medical content - biological samples, test results, and diagnoses - should be protected, private
and confidential.
Before continuing, the term informed consent needs to be defined. A major issue in the
medical world is variations on this definition, which results in patient decisions being made
based on an insufficient level of understanding. Informed consent insinuates that the patient has
been educated and completely understands the risks, benefits, efficacy, and alternatives of a
proposed procedure or test.1 Informed consent with respect to genetic testing also requires that
the patient understand the disorder(s) being tested for - including disease severity, treatability,
and variability - and how genetic samples will be stored, disposed of, and/or used after the test.1
If there are any intentions to use the sample for extraneous tests, this must be shared with the
patient, and the patient must give informed consent for those tests as well.1
In particular, extraneous testing of samples without informed consent is frequently cited
as a deterrent to genetic testing. Currently, there are minimal restrictions on how newborn
genetics samples can be stored and used after initial testing.1 Often, the remainder of these
samples are used to test new laboratory methods and collect population health data. Although it
is unlikely that this extra use of samples will be stopped - and frankly, it would not be beneficial
in the long run to eliminate this additional use of newborn samples - certain standards can be
upheld to protect patient autonomy. For example, it is typically required that samples be
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anonymized, and that the subsequent use not be anticipated at the time of sample collection.1
Should the use have been anticipated, informed consent would have been required. Enforcement
of these standards and continuous employment of informed consent can effectively eliminate this
as an issue in genetic screening programs.
Autonomy is by no means absolute - there are various circumstances in which a patient’s
right to autonomy may be overridden in their own best interest, or in the best interest of society
as a whole. In certain situations the patient is not capable of informed consent. In these instances,
designated surrogates - typically family members acting in the patient’s best interest - may
instead give consent.21-22 However, occasionally even the decisions of said surrogates may be
overridden to prevent severe harm to the patient.1 In instances in which the treatment or test is
relatively low risk, and a child is at risk of immediate danger, even parent refusal of treatment
can be ignored.1 This was confirmed by a ruling from the U.S. Supreme Court in response to a
Jehovah’s Witness families denying life-saving blood transfusions to fatally ill children: “while
parents are free to make martyrs of themselves, they are not free to make martyrs of their
children”.1
In the instance of early genetic testing, the patient - a newborn - is incapable of informed
consent. Typically, the newborn’s parents or legal guardians are his or her designated surrogates,
and are therefore capable of making a decision about screening. Based on previous limits to
surrogate control of autonomy, it might be argued that issues such as genetic screening should
not be controlled by surrogates, but instead by some universal ethical board. However, an
argument will be made later in this analysis to preserve patient autonomy and the right to choose
genetic screening, as it in general improves participation rates and overall patient satisfaction.
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One of the major issues associated with medical autonomy is the right to privacy. Privacy
is a condition of limited access to a person and/or information regarding them.1 In the medical
world, privacy requires confidentiality, or the assurance that certain sensitive information - such
as the results of genetic testing - will be protected.1 Such protections insinuate that access to said
information will be controlled by the patient or an authorized surrogate.
In reality, this is not always upheld. A major concern associated with genetic testing
relates to the education of family members who may also be affected by a heritable disease. A
patient may not wish to contact or disclose genetic information to certain family members, even
though this may not be in the relatives’ best interest. This often puts physicians in a difficult
ethical situation. Studies have shown that a significant percentage of physicians will disclose against a patient’s request - genetic information to relatives if they feel that the relatives are in
immediate danger.1 Although the study does not disclose which genetic diseases in particular
were analyzed, it can be inferred that most of them were conditions with diagnoses that were
traditionally considered life-changing and untreatable - for example, Huntington’s Disease. HH
has no such stigma, largely due to the fact that it is so simple to treat. Therefore, although the
issue of privacy is still relevant to HH screening, it is less of a concern than it would be in
screening for untreatable, stigmatized conditions. Further, if all newborns are tested, there will be
reduced concern about informing family members (as they will already be informed by testing of
their own newborn, should they have one).
As a whole, privacy and confidentiality are concerned with who has access to sensitive
information, and how that access is awarded.23 In the context of genetic screening, these concepts
are of paramount importance. Genetic information is directly related to an individual’s identity,
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and it is understandably disconcerting to believe that such information is available to random
strangers. As an extension of such concerns, a variety of moral and legal principles, including
federal and state laws, have been designed to protect patient autonomy and privacy.1
Despite these protections, absolute protection of privacy and confidentiality is near
impossible as a result of modern technology. For example, in the context of one hospital visit,
anywhere from dozens to hundreds of staff may have access to a patient’s private medical
records.24 After the visit, that number only increases as information is passed on to primary care
physicians and specialists, insurance companies, and public health organizations. Although it
may be impossible to provide absolute autonomy and privacy, that does not mean improvements
cannot be made to limit the number of individuals with access to sensitive information - such as
genetic testing results - and give the patient as much power as possible over result distribution.
Although this is a pressing bioethical issue, it applies to all medical testing and records, and is
therefore beyond the scope of this analysis - if individuals are willing to undergo routine medical
visits and testing, they are already exposing themselves to these issues.
As genetic screening becomes more commonplace, public health officials will face
increasing pressure to disclose genetic test results.10-11 However, this privacy violation comes at
the benefit of medical research and public health programs; it can be used to inform physicians
and researchers on how better to treat a variety of diseases, and how to distribute funding and
resources.8
At the heart of autonomy is the right to choose.25 Patients deserve the opportunity to
decide what tests and procedures they will undergo, how their genetic material will be used, and
who it will be shared with. However, certain circumstances require the limitation of autonomy in

10

the best interest of society. Although autonomy cannot be absolute, it can be preserved. At the
end of the day, an understanding of one’s genetic status with respect to heritable diseases is
necessary to fully exercise autonomy. However, even that decision - whether or not exercise full
autonomy - can also be protected.
Prior efforts to institute mandatory genetic screening for HH in Europe have failed for a
variety of reasons. It is possible that one is this clear violation to the fundamental principle of
autonomy: a mandatory screening program insinuates that patients will have no choice. In
reality, studies have shown that designating a screening program as mandatory does not
significantly increase the percent of individuals who participate.1 The general public will look
more favorably on a well-funded voluntary screening program, offered in conjunction with the
United States mandatory newborn screening panel, which preserves their surrogate autonomy
and right to informed consent. It is likely that more people will choose to participate - once they
understand the risks associated with the disease - than would take part in a mandated screening
program. To maximize protection of patient autonomy, any HH screening program should be
optional, and operate under the full guidelines of confidentiality, privacy, and informed consent.
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Justice
Medical justice refers to the overall fairness of medical practices and policies. Ideally, the
burdens and benefits of medicine will be distributed equally among all groups in society.20 Every
individual has an equal right to access basic social goods, including medical diagnosis and
treatment.11 However, unequal distribution of resources - including individual circumstances
such as socio-economic status, race, and geographic location - can reduce access to these social
goods. Discrimination and stigmatization as a consequence of genetic predisposition can further
reduce an individual’s ability to access medical treatment.
In order to effectively utilize the right to the basic social good of medical treatment, an
individual needs to understand his or her predisposition to genetic disorders and the appropriate
treatment options.11 In essence, this suggests that individuals must undergo screening to have full
access to medical justice and its resources. As other bioethical issues prohibit mandatory
screening, let us instead settle on the fact that the option to undergo screening is necessary for the
fulfillment of medical justice.
Discrimination is a prominent concern in the context of medical justice and genetic
testing. Historically, individuals with chronic or mental illness were involuntarily sterilized in the
United States.11 Although this process has long since been abolished, underlying fear that it will
return - or that it continues to occur without widespread knowledge - prevails. On a less extreme
level, modern discrimination is feared from employers, insurance companies, law enforcement
officials and society..1, 10-11 To avoid said discrimination, a variety of protective measures have
been instituted over the past several decades. All medical practices, procedures and policies
should conform to existing laws.20 If existing laws do not support the best interest of patients, it
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is the responsibility of physicians to instigate policy change that will further the patients’ best
interests according to the American Medical Association's Code of Medical Ethics.
Fear of discrimination in employment revolves around the belief that employers may
choose not to employ individuals predisposed to conditions that will require regular and
expensive treatment. Every year, the cost of providing health insurance for employees
increases.10 Predisposed employees will likely require more sick time benefits, and their ability
to do their job may decrease if they are genetically predisposed to certain debilitating
conditions.11 All of these notions suggest that employers have a strong financial incentive to
preferentially employ healthy individuals without predisposition to genetic disease. However,
employment is about an employee’s ability to fulfill a set of required tasks, and if an individual is
capable of fulfilling said tasks - irrelevant of their genetic predisposition - they should not be
discriminated against in hiring and firing decisions. To combat the concern of employment
discrimination, the Equal Employment Opportunity Commission was established in 1995 so that
employees experiencing discrimination on the basis of genetic predisposition could sue their
employers.
Discrimination on the basis of genetic testing amongst insurance carriers would likely
include required testing for some or all known genetic conditions and altered coverage, benefits
and premiums dependent on the results.11 Prior surveys suggest that many individuals already
believe that insurance companies frequently discriminate against individuals with pre-existing
conditions.11 These hypothetical increased healthcare costs violate the fundamental principle of
medical justice not only because they are discriminatory, but also because they reduce the
individual’s ability to access the universal social good of medical care. To combat the concern of
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insurance discrimination, the United States established various programs, including: HIPPA, the
Affordable Care Act (ACA), and the Genetifc Information Nondiscrimination Act (GINA). The
ACA prohibits discrimination by insurance carriers on the basis of pre-existing conditions.
GINA protects almost all individuals from genetic discrimination by both employers and insurers
- members of the military are the only exception.
Law enforcement officials may also discriminate on the basis of genetic predisposition.
However, this is perhaps the ideal circumstance for genetic discrimination: stored genetic data
can be used to identify criminals with nearly 100% certainty.10 DNA banks, originally intended
for use in identifying deceased members of the military, can also be used to identify cold case
criminals.1, 10
Finally, discrimination on a social level is also a concern with respect to genetic testig
and medical justice. Family members (including parents of infants), friends, potential spouses,
and other members of society may discriminate against individuals with known genetic
predispositions. This relates to the critical protection of patient autonomy and privacy; patients
have the right to control who, within society, is aware of their particular genetic predispositions.
In the specific case of HH, many of these concerns are insignificant. Individuals with HH
who begin an inexpensive and effective treatment protocol early in life are extremely unlikely to
experience debilitating complications, so well-informed employers and insurance companies are
unlikely to discriminate. The use of genetic information for discrimination by law-enforcement
and society, while somewhat difficult with respect to patient autonomy and privacy, is not a
significant source of negative discrimination either. All in all, it appears that discrimination is not
a pressing issue when considering a screening program for HH.
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On a related note, many groups have also encountered stigmatization on the basis of
genetic predisposition. Inherent to genetic diseases is their increased prevalence amongst certain
social groups.10 In some situations, said social groups feel stigmatized because they are targeted
for genetic testing. In extreme situations, minority groups may see recommendations to abort
affected fetuses or abstain from reproduction when affected by certain heritable conditions as a
form of genocide.1 Again, HH is an easily treatable and extremely common (as far as rare disease
go) condition, so these issues are altogether moot.
A major concern in medical justice is the fair distribution of scarce resources, especially
in the presence of competing needs.1, 20 In the context of genetic testing, scarce resources include
genetic specialists, testing facilities, and treatment centers. Trained genetic specialists are
particularly rare outside of large urban areas. Primary care physicians often order genetic tests
and interpret them without sufficient training because it is faster and cheaper than sending
patients to genetic specialists.11 However, this can result in incorrect interpretation of results and
undue worry for patients and their families.
Following diagnosis with a treatable genetic disease, it is expected that patients and their
families will pursue predictive and carrier testing of relatives and appropriate treatment
programs. In the United States, many states financially support screening programs, but do not
necessarily support coordinated treatment programs.1 As a result, some families feel that genetic
testing is irrelevant because treatment is not financially an option, and in fact only serves to
stigmatize their family. The treatment and constant monitoring necessary to prevent fatal damage
for many heritable diseases is expensive, and it makes some parents feel incapable of raising
their children.10 This prompts other ethical questions - should parents who cannot afford to treat
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their children be required to give up said children? Should they be forcibly sterilized so that they
do not have more children who they cannot treat?
All of these are pressing ethical concerns, but they are somewhat irrelevant in the context
of HH. As mentioned in the disease summary, treatment for HH is - in most US regions - free
and extremely effective. Assuming early diagnosis and regular blood donation, it is possible to
live a completely normal life without severe complications or medical debt. In fact, in the long
term it is cheaper to begin treatment early in life because patients will not incur medical costs
related to the severe, late-stage complications of untreated HH. Overall, with respect to the
bioethical principle of medical justice, HH appears to be an excellent opportunity to increase
medical justice by making more affected individuals aware of their condition and the resources
available to them, assuming that the entire population is also fully and accurately educated.
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Beneficence
Medical beneficence refers to the intent of doing good for a patient.20 In other words, all
decisions that medical providers make should be in the best interest of the patient. This requires
that medical providers be prepared, experienced, and qualified. At times it can be difficult to
determine what will bring about the greatest good for a patient; health is a complicated concept
that incorporates lifespan (mortality) and quality of life (morbidity).21
The critical extension of beneficence with respect to genetic testing is that screening must
result in an improvement in the patient’s life. This requires that a treatment be readily available,
and early intervention should result in reduced mortality and/or morbidity.22 There are hundreds
of genetic predispositions that cannot be treated, so testing for them may only introduce
unnecessary stress into the patient’s life. However, HH is easily treatable, and the treatment is
typically neither painful nor challenging to obtain.
Related to this is the question of when to inform parents and children of carrier or
predisposition status. Although it is currently common practice for parents to receive the results
of genetic testing (i.e. newborn screening) as soon as they are available, it may also be possible
to delay receipt of results until the child is old enough to comprehend them.1 For untreatable
diseases, it may eventually also be possible to delay receipt of results until adulthood, as being
informed earlier has no bearing on mortality or morbidity.1 In the case of HH, it is easy to justify
delaying release of screening results until later in life, as treatment does not begin until age
sixteen. Therefore, informing patients and their families at a later point in time - say, when the
patient is fifteen - will still provide the family adequate time to prepare for and treat the disease.
For many individuals, understanding genetic predispositions actually relieves stress. It allows the
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individuals to plan accordingly - financially and reproductively.9 At the end of the day, medical
beneficence is about increasing lifespan and improving quality of life; the impact of knowing
about a genetic disease may or may not relieve stress, depending on the individual and their
circumstances.25 This is why the protection of autonomy is so critical.
Medical beneficence also suggests that the primary motivation of genetic testing should
be to improve the patient’s life, not the lives of the patient’s relatives. For this reason, the
Institute of Medicine determined that newborn screening is only appropriate for treatable
conditions.11 Otherwise, parents might agree to newborn screening solely for the purpose of
planning future pregnancies, which does not benefit affected infants.11
Additionally, genetic testing can improve medical research and public health efforts.
Sharing data to improve population-health studies can better inform treatment plans, allocation
of resources, and emphasis during physician education.8 In particular, genetic testing at an early
age may allow patients to be tracked over the duration of their lives, providing more information
on disease progression and the physical, emotional, and social impact of genetic testing.1 Of
particular interest is how genetic testing will impact reproductive decisions, which requires
tracking from newborn genetic testing through reproductive age.1
Overall, the benefit of screening for HH is obvious - it saves lives. However, the ideal
timing of screening and receipt of results is somewhat less clear. Early genetic testing - typically
performed on newborns with a heel-stick blood test - is the only currently successful genetic
screening program. In diseases such as HH, in which the results are not needed until the patient
is approximately sixteen, testing could be delayed. However, prior investigation has suggested
that families are less likely to bring older children and teenagers back into a medical office for
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genetic screening, and the children themselves are more likely to refuse testing based on
unrelated issues, including a dislike of needles. Altogether, it is far simpler - and less expensive to simply test for HH and other late development conditions at the same time as newborn genetic
screening, which is already required and enforced by the United States.
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Non-maleficence
Medical nonmaleficence requires that a procedure do no harm to the patient or other
members of society.20 This requires an appreciation for the physical and emotional states of all
affected individuals, and an understanding of the future implications and possible complications
of the disease and any proposed treatments. If no treatment options are available, diagnosis may
exclusively promote discrimination and psychological distress. Hence, untreatable diseases are
rarely considered good options for early genetic testing.
If appropriate education and counseling is not provided to parents and children diagnosed
with genetic conditions, unnecessary distress may also ensue.1 For example, many non-medical
professionals do not understand the concept of genetic disease carriers. If a child is identified in
infancy as a carrier, parents may stigmatize the child, which can negate the benefit conferred by
understanding the family history of genetic disease.1 A major contributor to this issue is the fact
that primary care physicians are often the medical professionals ordering and interpreting genetic
tests.11 In reality, understanding genetic testing is extremely complicated, and genetic specialists
should be involved at every step to maximize medical nonmaleficence. However, this conflicts
with medical justice, as not all groups will have access to said genetic specialists. A potential
intermediate solution is improving education of primary care physicians with respect to genetic
testing, which will improve the accuracy of their interpretations.
Clear interpretation and communication of genetic results is particularly important
because affected individuals may view themselves as “defective” or “damaged”.1 This can affect
the emotional state of the individual and their family. In the case of childhood diagnosis,
uneducated parents may inappropriately stigmatize affect children, leading to fewer financial
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resources and social support for those children.1 This is important even with respect to diseases
such as HH, which have minimal detrimental effects when treated. If physicians and patients are
not clearly educated about the disease and its treatment, they may experience unnecessary
psychological suffering.
On the technical side of genetic testing, there is great concern over false results. In
general, the issue is not false negatives (individuals who have the mutation but were not
identified), but instead is false positives (individuals who do not have the mutation but were
identified). False positives can result in confusion and lifelong anxiety for both patients and their
families, especially if the results are not clearly explained or confirmed.1 With respect to HH, the
treatment is minimally painful and beneficial to society, so even individuals identified by way of
false positive test results should be minimally affected.
Genetic testing may also reveal unusual family dynamics. Typically, this occurs when
children are adopted or the biological father is not the spouse of the biological mother.1, 22 In
autosomal recessive diseases such as HH, both biological parents must carry at least one mutant
copy of the gene for the child to inherit the disease. If one of the child’s parents does not test
positive for the gene, it is highly unlikely that that parent is biologically related to the child. This
can be disruptive to both children and parents. A potential solution to this issue is delaying
release of the test results and/or not requiring parents of affected children to be tested. However,
this does not eliminate the possibility that the child may find out about their alternative family
status at a time prior to when they might otherwise find out.
Overall, there is minimal concern that HH genetic screening will result in additional
physical or emotional duress that is not already applied to these families as a result of the
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mandated United States newborn screening program. By making the screening of additional
diseases voluntary and improving educational programs, families sensitive to emotional distress
as a result of disease diagnosis can decide for themselves if screening is the best option for their
family.
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Conclusion
Genetic disease is often a silent killer. In the case of HH, that does not need to be true.
Although genetic screening is a complex bioethical issue, HH appears to be an ideal candidate.
By establishing a screening protocol that encourages voluntary choice after thorough education
and informed consent, along with working to establish and enforce additional privacy protection
standards, a HH screening program will satisfy patient autonomy. By educating additional
genetic specialists and all social groups - physicians and patients - the program will satisfy
medical justice. Based on the ease and effectiveness of the treatment, an HH screening program
will easily satisfy beneficence. And finally, assuming a voluntary program, it will also satisfy
nonmaleficence by giving individuals the choice to protect their emotional state, if that is of
major concern to them.
One major improvement in the medical system that needs to occur with or prior to
establishment of this program is increased educational measures geared towards both patients
and physicians. Awareness is critical for patients to understand why diagnosis is necessary, how
to receive treatment and make the most of resources, and how to support family members as they
undergo the screening process. Similarly, if physicians are unaware of the dangers that a disease
poses, they are not capable of protecting their patients effectively, which leaves them vulnerable
to legal consequences.1 Although informed consent will become increasingly challenging as
more disorders are tested for simultaneously, it is absolutely critical that the time and resources
are taken to ensure that it is preserved. It is very possible that part of this increasingly complex
process will be an option to delay receipt of testing results, which will give families time to
further research and understand the implications of their diagnosis status.
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By screening for HH, we have the opportunity to massively reduce mortality and
morbidity in the United States, and possibly across the globe. Although versions of an HH
screening protocol have been proposed and denied across Europe, the United States is often
considered a leader in innovative medicine and prevention techniques. An established, successful
screening protocol in the United States will set a strong standard for other countries to follow.
Ideally, in the next decade, screening programs for HH and many other genetic diseases will be
established globally so that affected individuals can begin receiving the treatment that they need
and deserve.
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